SLFN11 and cancer: Based on bioinformatics analyses associated with the Cancer Cell Line Encyclopedia (CCLE) and the National Cancer Institute Antitumor Cell Line Panel (NCI-60), SLFN11 appears to be a key factor in response to several anticancer drugs, including DNA synthesis inhibitors (gemcitabine, cytarabine), alkylating agents (chlorambucil, melphalan, cisplatin, carboplatin, carmustine), topoisomerase I inhibitors (topotecan, irinotecan), and topoisomerase II inhibitors (mitoxantrone, etoposide, daunorubicin, doxorubicin) 11, 26, 34.